Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.33 |
| ▸ | WNT3A | P56704 | 4/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6142521 | 0.93 | ALDH1A1 (0.33) | KMT2AMEN1RXRACTNNB1WNT3A | |
| SCHEMBL925393 | 0.84 | AVPR1A (0.37) | KMT2AMEN1ROCK2MAPTALDH1A1 | |
| SCHEMBL14357334 | 0.83 | ATM (0.50) | KMT2AMEN1RXRACTNNB1WNT3A | |
| SCHEMBL30563103 | 0.82 | GNG2 (0.40) | KMT2AMEN1RXRACTNNB1WNT3A | |
| SCHEMBL829418 | 0.82 | GNG2 (0.40) | KMT2AMEN1RXRACTNNB1WNT3A | |
| SCHEMBL27636279 | 0.82 | ATM (0.36) | KMT2AMEN1RXRACTNNB1WNT3A | |
| SCHEMBL6142523 | 0.81 | MEN1 (0.33) | KMT2AMEN1ROCK2ATMMAPT | |
| SCHEMBL14898029 | 0.81 | RXRA (0.50) | KMT2AMEN1RXRAKDM4EMAPK1 | |
| SCHEMBL17660491 | 0.81 | ROCK2 (0.38) | KMT2AMEN1ROCK2KDM4EMAPK1 | |
| SCHEMBL27517967 | 0.80 | L3MBTL1 (0.38) | KMT2AMEN1KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-7776895-B2 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2042168-A1 | Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2039700-A2 | Novel anti-inflammatory androstane derivatives | Glaxo Group Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | disclosed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| US-20050054622-A1 | Novel anti-inflammatory androstane derivatives | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040248867-A1 | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives | GLAXO GROUP LIMITED (GB) | 2004-12-09 | — | — | US | disclosed |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| CN-1501911-A | Phenethanolamine derivatives for treatment of respiratory diseases | — | 2004-06-02 | — | — | CN | disclosed |
| EP-1366025-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002070490-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | NR5A1, HSD17B7, HSD17B1 | KMT2A 3721/4885MEN1 4075/4885RXRA 300/4885 |
| US-20040248867-A1 | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives | HSD17B1, NR5A1, HSD17B7 | KMT2A 3586/4885MEN1 4431/4885RXRA 213/4885 |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | KMT2A 171/4885MEN1 1655/4885RXRA 1434/4885 |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | ADRB1, ADRB2, ADRA1A | KMT2A 4437/4885MEN1 3712/4885RXRA 802/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | KMT2A 257/4885MEN1 3658/4885RXRA 970/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | KMT2A 369/4885MEN1 1526/4885RXRA 1334/4885 |
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | KMT2A 95/4885MEN1 1073/4885RXRA 2383/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | KMT2A 171/4885MEN1 1655/4885RXRA 1434/4885 |
| US-20050054622-A1 | Novel anti-inflammatory androstane derivatives | NR5A1, HSD3B2, HSD3B1 | KMT2A 3586/4885MEN1 4400/4885RXRA 163/4885 |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | PNMT, CHRM3, HRH4 | KMT2A 108/4885MEN1 3525/4885RXRA 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.